Back to Authors

Vera, Renzo E.

Mayo Clinic

Division of Oncology Research,

Citations 12

TFII-I-mediated polymerase pausing antagonizes GLI2 induction by TGFβ
McCleary‐Wheeler, Angela L. , Paradise, Brooke D., Almada, Luciana L. , Carlson, Annika J, Marks, David L. , Vrabel, Anne M., Vera, Renzo E., Sigafoos, Ashley N. , Olson, Rachel , Fernández-Zapico, Martín E. , Vrabel, Anne, Olson, Rachel L

Nucleic Acids Research | May 26, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/nar/gkaa476 Get It

AbstractThe modulation of GLI2, an oncogenic transcription factor commonly upregulated in cancer, is in many cases not due to genetic defects, suggesting dysregulation through alternative mechanisms. The identity of these molecular events remains for the most part unknown. Here, we identified TFII-I as a novel repressor of GLI2 expression. Mapping experiments suggest that the INR region of the GLI2 promoter is necessary for GLI2 repression. ChIP studies showed that TFII-I binds to this INR. TFII-I knockdown decreased the binding of NELF-A, a component of the promoter–proximal pausing complex at this site, and enriched phosphorylated RNAPII serine 2 in the GLI2 gene body. Immunoprecipitation studies demonstrate TFII-I interaction with SPT5, another pausing complex component. TFII-I overexpression antagonized GLI2 induction by TGFβ, a known activator of GLI2 in cancer cells. TGFβ reduced endogenous TFII-I binding to the INR and increased RNAPII SerP2 in the gene body. We demonstrate that this regulatory mechanism is not exclusive of GLI2. TGFβ-induced genes CCR7, TGFβ1 and EGR3 showed similar decreased TFII-I and NELF-A INR binding and increased RNAPII SerP2 in the gene body post-TGFβ treatment. Together these results identify TFII-I as a novel repressor of a subset of TGFβ-responsive genes through the regulation of RNAPII pausing.
Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma
Chen, Gang , Nakamura, Ikuo , Dhanasekaran, Renumathy , Iguchi, Eriko , Tolosa, Ezequiel J. , Romecín, Paola , Vera, Renzo E., Almada, Luciana L. , Miamen, Alexander G., Chaiteerakij, Roongruedee , Zhou, Mengtao , Moser, Catherine D., Han, Shaoshan , Hu, Chunling , Banini, Bubu A. , Oseini, Abdul M., Fang, Yong , Yang, Dongye , Shaleh, Hassan M., Wang, Shaoqing , Wu, Dehai, Song, Tao , Lee, Ju‐Seog , Thorgeirsson, Snorri S., Chevet, Éric , Shah, Vijay H. , Fernández-Zapico, Martín E. , Roberts, Lewis R. , Romecin, Paola A, Asiedu, Michael K. , Chen, Yichun, Nakamura, Ikuo, Chaiteerakij, Roongruedee , Chen, Yi‐Chun , Roberts, Lewis R , Dhanasekaran, Renumathy , Hu, Chunling , Chen, Gang , Chevet, Eric

Cancer Research | November 21, 2016 | Volume: 77 | Issue: 3 | Pages: 632-645

10.1158/0008-5472.can-15-2556 Get It

Abstract Existing antiangiogenic approaches to treat metastatic hepatocellular carcinoma (HCC) are weakly effectual, prompting further study of tumor angiogenesis in this disease setting. Here, we report a novel role for sulfatase 2 (SULF2) in driving HCC angiogenesis. Sulf2-deficient mice (Sulf2 KO) exhibited resistance to diethylnitrosamine-induced HCC and did not develop metastases like wild-type mice (Sulf2 WT). The smaller and less numerous tumors formed in Sulf2 KO mice exhibited a markedly lower microvascular density. In human HCC cells, SULF2 overexpression increased endothelial proliferation, adhesion, chemotaxis, and tube formation in a paracrine fashion. Mechanistic analyses identified the extracellular matrix protein periostin (POSTN), a ligand of αvβ3/5 integrins, as an effector protein in SULF2-induced angiogenesis. POSTN silencing in HCC cells attenuated SULF2-induced angiogenesis and tumor growth in vivo. The TGFβ1/SMAD pathway was identified as a critical signaling axis between SULF2 and upregulation of POSTN transcription. In clinical HCC specimens, elevated levels of SULF2 correlated with increased microvascular density, POSTN levels, and relatively poorer patient survival. Together, our findings define an important axis controlling angiogenesis in HCC and a mechanistic foundation for rational drug development. Cancer Res; 77(3); 632–45. ©2016 AACR.